



# Bluetongue (BT) & Lumpy Skin Disease (LSD) in the EU

*(2014-Nov 2016)*

*Dimitrios DILAVERIS  
European Commission  
Directorate-General for Health and Food Safety  
G3 – Official controls and eradication of diseases in animals*




# Bluetongue (BT) in the EU




European  
Commission

## Bluetongue outbreaks in 2014 (ADNS)




## Bluetongue outbreaks in 2015 (ADNS)



# Bluetongue outbreaks in 2016

(ADNS, situation as at  
28 Nov 2016)





## BT zoning – end of 2014

### Bluetongue

Restricted zones\* as of 09 December 2014


This map includes information on the bluetongue virus serotypes circulating in each restricted zone, which permits, for the purposes of Articles 7 and 8 of Regulation No 1266/2007, the identification of the restricted zones demarcated in different Member States where the same bluetongue virus serotypes are circulating.

#### Zone (serotypes)

- G (1,2,4,16)
- I(1,4)
- J (1)
- T (1,2,4,8,16)
- X (4,16)
- Z (1,16)
- A1 (1,2,4,9,16)
- A2 (1,2,16)
- A3 (4)
- A4 (1,4,8,16)
- A5 (1,2,9,16)

\* as defined in Article 2 (d) of Commission Regulation No 1266/2007: geographic areas where surveillance and/or protection zones have been demarcated by the Member States in accordance with Article 8 of Council Directive 2000/75/EC.

For information purposes only.  
The European Commission does not assume any liability resulting from its content.





## BT zoning – end of 2015

### Bluetongue

Restricted zones\* as of 10 December 2015


This map includes information on the bluetongue virus serotypes circulating in each restricted zone, which permits, for the purposes of Articles 7 and 8 of Regulation No 1266/2007, the identification of the restricted zones demarcated in different Member States where the same bluetongue virus serotypes are circulating.

#### Zone (serotypes)

- F(8)
- G (1,2,4,16)
- I(1,4)
- J (1)
- T (1,2,4,8,16)
- X (4,16)
- Z (1,16)
- A2 (1,2,16)
- A3 (4)
- A4 (1,4,8,16)
- A6 (1,4,16)

\* as defined in Article 2 (d) of Commission Regulation No 1266/2007: geographic areas where surveillance and/or protection zones have been demarcated by the Member States in accordance with Article 8 of Council Directive 2000/75/EC.

For information purposes only.  
The European Commission does not assume any liability resulting from its content.





## BT zoning – early Nov 2016

### Bluetongue

Restricted zones\* as of 03 November 2016


This map includes information on the bluetongue virus serotypes circulating in each restricted zone, which permits, for the purposes of Articles 7 and 8 of Regulation No 1266/2007, the identification of the restricted zones demarcated in different Member States where the same bluetongue virus serotypes are circulating.

#### Zone (serotypes)

- F(8)
- G (1,2,4,16)
- H (Not specified)
- I(1,4)
- J (1)
- T (1,2,4,8,16)
- X (4,16)
- Z (1,16)
- A2 (1,2,16)
- A3 (4)
- A4 (1,4,8,16)
- A6 (1,4,16)

\* as defined in Article 2 (d) of Commission Regulation No 1266/2007: geographic areas where surveillance and/or protection zones have been demarcated by the Member States in accordance with Article 8 of Council Directive 2000/75/EC.

For information purposes only.  
The European Commission does not assume any liability resulting from its content.






# **Lumpy skin disease in the EU**




## LSD situation in 2013 - 2015    Disease spread



**LSD situation in 2015:**

**1<sup>st</sup> Occurrence in continental Europe (Greece , 117 outbreaks, Aug-Dec 2015)**





## LSD epidemiological situation January to 30 Nov 2016 (ADNS + country reports)

### LSD outbreaks in SE Europe (April – early Oct 2016)

- Greece : **104**  
(last on 25/11/2016)
- Bulgaria : **217**  
(last on 1/8/2016)
- FYROM : **1591** (Sep report)
- Serbia: **221**  
(last on 3/09/2016)
- Kosovo\*: **76** (Aug report)
- Montenegro: **> 400**
- Albania: **1516** (Sep report)

( \* This designation is without prejudice to positions on status, and is in line with UNSCR 1244 and the ICJ Opinion on the Kosovo Declaration of Independence).

 **LSD outbreaks**  
01.01-30.11.2016 (ADNS)





## **LSD Situation as at November 2016**

- Further spread of LSD to the north or west seems to be halted for this year (vaccination + winter)
- No new LSD outbreaks reported in those affected countries where full vaccination coverage has been achieved
- Disease spread reported from countries with low vaccine coverage (e.g. Albania) , also sporadic cases reported from the former Yugoslav Republic of Macedonia and isolated cases in non-vaccinated animals (e.g. Greece)
- All affected countries where vaccination is still in progress put their efforts to complete their vaccination campaign as soon as possible and achieve high vaccine coverage.






## LSD vaccination – Situation as at mid Nov 2016


### Vaccination completed in:

- Bulgaria
- Greece (Northern part)
- Serbia
- FYROM
- Montenegro
- Kosovo
- Croatia

### Vaccination in progress in

- Albania
- Southern part of continental Greece

-  Vaccination Completed
-  Vaccination in progress
-  LSD outbreaks as at 1 Jan -14 Nov 2016 (ADNS)





## **Two Decisions adopted 15 November 2016**

Official Journal of the European Union

---

**COMMISSION IMPLEMENTING DECISION (EU) 2016/2008**

**of 15 November 2016**

**concerning animal health control measures relating to lumpy skin disease in certain Member States**

*(notified under document C(2016) 7023)*

Official Journal of the European Union

---

**COMMISSION IMPLEMENTING DECISION (EU) 2016/2009**

**of 15 November 2016**


**approving the vaccination programmes against lumpy skin disease submitted by the Member States**

*(notified under document C(2016) 7219)*





**LSD zoning CID (EU) 2016/2008 & CID (EU) 2016/2009, adopted 15 Nov 2016.**





**THANK YOU !!!!**

